CD371-specific/YSNVz/I-18 CAR T cells

Cohorts will be infused with escalating doses of CD371-specific/YSNVz/IL-18 CAR T cells with lymphodepleting chemotherapy (LDC) to establish the maximum tolerated dose (MTD). There is a third, lower dose level (step-down dose) available for dose de-escalation in the event of severe toxicity at the first planned dose level.

The purpose of this study is to find out whether CD371-YSNVZ-IL18 CAR T cells are safe, and to look for the highest dose of CD371-YSNVZ-IL18 CAR T cells that cause few or mild side effects in participants.

Live record on ClinicalTrials.gov →

• Subject Inclusion: Collection of T cells (Part A)
• History of CD371+ AML
• Any disease status is eligible for collection
• Expression of CD371 at any level on AML blasts (any method of detection including IHC and/or flow cytometry)
• Pediatrics: ≥ 1 year and ≥ 10kg for collection
• Adults: no limit on age/weight for collection

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.